Member Info for GLTader

Wow - big volume today and this week actually. Corporate activity? At this price, Vodafone is definitely a target!
The sum of parts - evidenced by offers for Vantage Towers and Italian business alone - makes Vodafone susceptible to being bought and split up!
Enjoy the ride.

Well, if YGEN management is reading this BB (still), do something about the share price of our company please. And yes, you can affect it. We know it is as much in the interest of management and employees, as well as your shareholders.
Still a 2.5% holder!

Perhaps someone will now buy us up for $200m!
4x sales
8x GP
I will take that. :-)

Given POO above $100, I imagine BP will deliver $12-15bn of RC profits / cash flow this year even without Rosneft.
Intrigued with the sudden fall around 1.30pm today into the end of day, after rising significantly in the morning. Anyone any ideas? Can't find any news related items.....
Amazingly, BP is still 30% off pre-Covid levels!
What people don't realise is that as the world and definitely Europe, tries to reduce / remove dependency on Russian oil, companies like BP and Shell, will be more relied upon. Add to this BP's more aggressive move into renewables, I must confess I find it baffling we are where we are SP wise.
Oh well, will enjoy the dividends and buy backs whilst I wait for 500p.
Good luck all.

....Chevron hits 5-year high at $149, whilst BP languishing at 30% below pre-Covid!
The value should tell and SP should reflect it accordingly. BP is now a "clean" company with good dividend yield and $4bn / year buybacks, and that's on $60/barrel. We are $105.

As sad as the circumstances may be, think BP did a masterstroke. It will detach itself from the risk in its portfolio, taking a hit now whilst it can absorb it, and going forward, be a much cleaner (in all senses) company. It will also appease many different stakeholders.
I agree with the SeekingAlpha article that BP share price already baked in the risk - no doubt it will have a wobble in the morning but once the dust settles, investors will be back in especially with POO so high and wouldn't be surprised we end up higher if not on the day, in the days to come. I know a lot who were worried re the link to Russia, are now considering buying.
BP has maintained its dividends, buybacks and financial framework, based on POO at $60 and without Rosneft.

https://www.bp.com/content/dam/bp/business-sites/en/global/corporate/pdfs/news-and-insights/press-releases/bp-to-exit-rosneft-shareholding.pdf

https://www.thetimes.co.uk/article/186579b6-970e-11ec-addf-533e9597e348?shareToken=d97291d33c3ff5245218181ed29af363

In light of news BP will offload.....perhaps the Chinese.......?
The asset value was already deemed risky when Russia invaded Ukraine. Hence BP got affected the most despite the strong oil price.
We may experience a dip in the morning but actually will strengthen BP long term - even if we get half value, may get special distribution?

Agree Ctw2014.
From the RNSs released and investor presentations, there is no bad news out there, yet retail investors are looking for it due to emotional effect of deterioration in SP fuelling exit, which in turns, exacerbates the situation. The CTDA desktop review / approval was much ado about nothing.
As already announced, we will be delivering record revenue in FY21/22, healthy EBITDA, with a possibility of break even at OPAT level, again first in YGEN history.
We have primed ourselves to grow on our core, whilst leveraging facilities built to enhance genomic services. Whilst Covid testing may wane, genomic sequencing will not. US launch will be huge. International markets back to growth.
The recent Walbrook concensus forecasts for FY22/23 and FY23/24 are encouraging and I hope we will be beating those, like we have been whole of FY21/22.
When this SP momentum turns, it will be rapid and I am hopeful we will be back to mid-teens in quick order.
All the best.

At this rate, we will be swallowed up - petty cash for some of the larger players......

Thanks Ciccio for posting. This is deemed low.

But even at this level, it puts Vodafone as a whole at circa €100bn or £85bn EV if proportionately calculated by revenue. This mean equity value of £47bn ex debt versus market cap of £37bn today ie 27% upside or 177p. Of course, we know this undervalues to consolidation play benefits. Very simplistic calculations as Italy is hardly the growth market, but a basis nonetheless.

It is no wonder analysts are coming up with sums of parts valuation and upgrading targets which are between 165p (low) - 230p (high). Based on above, 200p is possible.

Bakky - so from your interpretation, is it just the Clarigene test kit that is a question mark? Well, that is not big business. It is the lab testing and genetic sequencing that is of significant value. Regardless, as I said, we are reporting record revenues so......

Far from being an advisor to anyone in this BB, I would urge people to read the recent H1 results, listen to IMC video, look at the developments over the last 12-18 months, recent trading update, scaling up of business news and accelerated foray into US. Don't let the share price emotionally skew your assessment of the business performance to date and expected going forward.

I mentioned recently the acquisition of Genmark Diagnostics by Roche for $1.8bn, representing circa 9x sales and the company was still reporting a loss. Why - probably because gross margin is circa 40% and they are growing, and for Roche, the rest of overhead can probably go as they absorb operations and distribution channels. Putting the maths another way, it is circa 22x gross profits. YGEN will be reporting, I reckon, in excess of £20m gross profits for FY22 on revenue of £37m. So, do your own maths even on a discounted multiple.

Bakky rightly calls out his sleuthing - I am not an expert in CTDA or related legislations. All I know is that you can't continue to perform lab testing and report it as recently as January, under contracts procured by the same DHSC who issued those legislations. It makes no sense both ways. Perhaps YGEN is using Thermo / Illumina machines and tests since November - no harm there! And sequencing is presumably ok, which is even more lucrative and set to continue.

I have no idea why our SP performance is so poor - daily volume isn't heavy but its the continued drip selling and I can only put that to retail investors exiting and MM are catching that sentiment. Or perhaps there is a seller in the background. Who knows but it will stop at some point. I invest based on fundamentals - have worked well for me for years - and based on that, I will be holding / adding YGEN at this point. I won't exit until we are at least 20p+ unless the fundamentals changed. At this price, wouldn't be surprised if one of the larger players swallow us on the cheap.

Good luck all.

A range and I am holding (and adding) until we realise 20p+.

Dear of dear. This BB is killing its own share price.
If Yourgene reading this, please do release RNS to confirm validity of your activities to close this loop. I know you already said you continue to provide testing and are doing sequencing, but just close the loop please.
In the meantime, I remain confident in your progress and keep at it.
Thank you (a 2% holder)

This board amazes me, and quite frankly, as depressing as the YGEN share price! You lot talk your own share down.
YGEN has just and will report record revenues, with healthy EBITDA, possibly break even at reported OPAT level for the first time in its history.
We are just only advancing into the US, with three large clients on board with sales expectation that could overtake international sales of non-Covid income, EKF strategic partnership and distribution agreement.
Genetic sequencing / lab tests in UK will continue whether Covid or non-Covid.
LR and team - keep up the good work operationally. Now, get the world to take note and fix the SP!
Thanks.

My goodness, I am getting quite disappointed with this forum. I know the share price is clouding everyone's sentiments and views, but take a moment to reflect. YGEN have just told us that they will report at least £37m revenue, with at least 10% EBITDA. By that, and given track record this financial year, I take it we will be at least meeting that, likely beating it.

Natdan - you pointed out the difference in 2021 v 2022 update. Well, firstly, there is more to explain when you miss expectations. Secondly, and more accurately, Lyn said he will update us all in January about trading performance - this following the HY results and conference all on 14 December 2021. This is specifically to address questions from the floor how busy Covid will be and size of the DHSC contracts. He said these contracts have no minimum order values so hard to tell, but he will update us as soon as he knows more. Well he just did!

Anyone who has already forgotten should refresh themselves by reading HY results, and listening to the IMC video. I just did. For your convenience, there are many growth drivers to come:
- US NIPT launch: should be live this quarter and fully from 1 April 2022. I expect this to quite quickly overtake the international NIPT sales given the quality of the partner, a leading precision medicine company launching a network of new clinical reproductive health screening across all US states. Think they only do it with minimum 80,000/annum per clinic;
- US x 2 Ranger technology clients (with more to come): Lyn said investments being made to relocate and expand Yourgene Canada to accommodate expected sales. He specifically said currently 500 cassettes (consumables) per month, ramping it up to 5,000 per month, as requested by Labcorp + ANO (to be named). More pipeline;
- Other tests: New distribution partners in ME, US and LATM, plus key hires;
- Re-applying facility for non-Covid testing and genetic sequencing: Of the tenders in, 30% are non-Covid. This is even though company expect Covid and Covid related needs to continue for the next 2 years, which I tend to agree. The DHSC contracts only serves to validate YGEN capability and will be door openers;
- Debt financing to avoid dilution for further M&A: Institutions only lend if you can provide reliable CF!

I am equally frustrated with SP performance, and I imagine so are the management! They are doing everything they feel they can and are delivering, yet not being cheered. Well, I say thank you Lyn and YGEN team for delivering us £37m revenue. Genmark Diagnostics which I referenced the other day was sold for 9x sales, and guess what, they are loss-making!

There appears to be a seller in the background since turn of year. I suspect employee/ex-employee perhaps who had options exercised at cheaper price - ppl have their reasons. Once that clears, the SP should follow the progress of the business. I have no doubt, if we crack US as expected, we will be growing further and quickly in FY22.

Firstly, whilst UK may be relaxing testing inbound because either cases are already so prevalent or we want to learn to live with it, it makes it more likely other countries will require PCR tests from UK arrivals. So, the outbound tests will still be active for the rest of the year I reckon. Additionally, as number of tests reduce - it will not disappear as testing will be here to stay for Covid or any other respiratory diseases as we learn to live with it - I suspect there will be consolidation in this space leaving only the pure plays (ie YGEN) doing the testing. All the "pop ups" will slowly dissipate.
We are into genetic testing, so it is not just Covid.

Not sure anyone here remembers Osmetech, a molecular diagnostics company listed in AIM and SP struggling here. Had proprietary diagnostic machines and tests. Delisted from here and listed in US as Genmark Diagnostics. I do, as I was invested in it and exited when it delisted!
Was bought by Roche for $1.8bn in 2021. Sales was forecast to be $180-200m in FY2021. 9x sales!
Well, YGEN business & offering is not dissimilar..........

Bakky - are you asserting that the DHSC which contracted YGEN for winter surge testing (RNS 23 Dec 2021), contract which is in the public domain, is the same DHSC preparing approved list which YGEN isn't on but they contracted them? :-))